Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.
作者信息
Filippi Massimo, Capra Ruggero, Centonze Diego, Gasperini Claudio, Patti Francesco, Perini Paola, Pozzilli Carlo, Rocca Maria A, Uccelli Antonio, Trojano Maria
机构信息
Neurology Unit, MS Center, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy.
Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
出版信息
J Neurol. 2021 Apr;268(4):1540-1543. doi: 10.1007/s00415-021-10466-0. Epub 2021 Feb 20.
Abstract
摘要
相似文献
1
Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus.奥瑞珠单抗治疗多发性硬化症患者的治疗建议及季节性流感疫苗：专家共识
J Neurol. 2021 Apr;268(4):1540-1543. doi: 10.1007/s00415-021-10466-0. Epub 2021 Feb 20.
2
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.奥瑞珠单抗对多发性硬化症患者疫苗反应的影响：VELOCE 研究。
Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29.
3
Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.读者回应：奥瑞珠单抗对多发性硬化症患者疫苗反应的影响：VELOCE研究
Neurology. 2021 May 4;96(18):870. doi: 10.1212/WNL.0000000000011867.
4
Author Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study.
Neurology. 2021 May 4;96(18):870. doi: 10.1212/WNL.0000000000011868.
5
Ocrelizumab for the treatment of multiple sclerosis.奥瑞珠单抗治疗多发性硬化症。
Expert Rev Neurother. 2019 Feb;19(2):97-108. doi: 10.1080/14737175.2019.1561284. Epub 2018 Dec 28.
6
Ocrelizumab for multiple sclerosis.奥瑞珠单抗治疗多发性硬化症。
Drug Ther Bull. 2018 Jul;56(7):80-84. doi: 10.1136/dtb.2018.7.0646.
7
Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.多发性硬化症患者在接受免疫调节治疗时对季节性流感疫苗的抗体反应。
Eur J Neurol. 2018 Mar;25(3):527-534. doi: 10.1111/ene.13537. Epub 2018 Jan 6.
8
[Ocrelizumab for treatment of multiple sclerosis].奥瑞珠单抗用于治疗多发性硬化症
Nervenarzt. 2020 Aug;91(8):722-734. doi: 10.1007/s00115-020-00937-6.
9
[Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report].
Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):116-120. doi: 10.17116/jnevro2018118082116.
10
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.利妥昔单抗是治疗多发性硬化症的一种可接受的奥瑞珠单抗替代药物——否。
Mult Scler. 2018 Aug;24(9):1159-1161. doi: 10.1177/1352458518757931. Epub 2018 Feb 22.
引用本文的文献
1
Influenza Vaccination among Multiple Sclerosis Patients during the COVID-19 Pandemic.新冠疫情期间多发性硬化症患者的流感疫苗接种情况
Vaccines (Basel). 2022 Oct 21;10(10):1766. doi: 10.3390/vaccines10101766.
2
Case Report: Covid-19 in Multiple Sclerosis Patients Treated With Ocrelizumab: A Case Series.病例报告：接受奥瑞珠单抗治疗的多发性硬化症患者中的新型冠状病毒肺炎：病例系列
Front Neurol. 2021 Oct 20;12:691616. doi: 10.3389/fneur.2021.691616. eCollection 2021.
3
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology.奥瑞珠单抗治疗多发性硬化症：安全性、有效性及药理学
Ther Clin Risk Manag. 2021 Jul 30;17:765-776. doi: 10.2147/TCRM.S282390. eCollection 2021.
Zotero 插件